Trials / Recruiting

RecruitingNCT05046483

Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI

Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes Mellitus After New Onset of ST-Segment Elevation Myocardial Infarction (STEMI) (DISTEMI Study)

Status: Recruiting
Phase: —
Study type: Observational
Enrollment: 300 (estimated)

Sponsor: German Diabetes Center · Academic / Other
Sex: All
Age: 18 Years – 80 Years
Healthy volunteers: Accepted

Summary

The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to characterize in detail the clinical, metabolical, immunological and vascular phenotype, investigate the interplay between myocardial remodelling and the metabolic phenotype, monitor the progression of the disease and compare the phenotype of STEMI people with diabetes mellitus to people with prediabetes and glucose tolerant people.

Detailed description

In detail, the following questions will be answered: 1. Do distinct metabolic phenotypes (with respect to insulin secretion, insulin sensitivity, circulating free fatty acids and ectopic lipid storage, especially in the liver) determine myocardial infarct size and decline of contractile function of the remote myocardium? 2. Which factors modify the progression of the disease (insulin resistance, ectopic lipid storage, subclinical inflammation, abnormal energy metabolism)? People are thoroughly examined at baseline and one year after STEMI. 3. Can we identify risk profiles and their relevance for development of diabetes-associated complications as well as long-term progression of diabetes? 4. Can we improve risk assessment algorithms for targeted therapy in line with Precision Medicine?

Conditions

Timeline

Start date: 2018-12-30
Primary completion: 2028-12-30
Completion: 2029-12-30
First posted: 2021-09-16
Last updated: 2023-08-22

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT05046483. Inclusion in this directory is not an endorsement.